Drug Device Combination Products Market by Type (Injectable, Transdermal Patch, Infusion Pump, Drug-eluting Stent, Inhaler), Application (Diabetes, Oncology, Pain, Opthamology), End User (Hospital, Home Care), and Region - Global Forecast to 2030

1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Segments Considered & Geographical Scope
1.3.2 Inclusions & Exclusions
1.3.3 Years Considered
1.3.4 Currency Considered
1.4 Stakeholders

2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Sources of Secondary Data
2.1.1.2 Key Data from Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Objectives of Primary Research
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Revenue Share Analysis (Bottom-Up Approach)
2.2.2 Mnm Repository Analysis
2.2.3 Company Investor Presentations and Primary Interviews
2.2.4 Top-Down Approach
2.3 Market Growth Rate Projection
2.4 Data Triangulation
2.5 Study Assumptions
2.6 Research Limitations
2.7 Risk Analysis

4.1 Drug Device Combination Products Market Overview
4.2 Asia-Pacific: Drug Device Combination Products Market, by Application and Country
4.3 Drug Device Combination Products Market: Geographic Growth Opportunities

5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Rising Prevalence of Chronic Diseases
5.2.1.2 Growing Adoption of Biologics and Vaccines
5.2.1.3 High R&D Investments from Government Organizations and Private Bodies
5.2.1.4 Shift Toward Personalized Medicines and Patient-Centric Care
5.2.1.5 Rising Popularity of Self-Administered Medicines
5.2.2 Restraints
5.2.2.1 Stringent Regulatory Policies and Compliance Hurdles
5.2.2.2 Focus on Alternative Drug Delivery Methods
5.2.3 Opportunities
5.2.3.1 Increased Preference for Minimally Invasive Products
5.2.3.2 High Growth Potential in Emerging Economies
5.2.3.3 Growing Adoption of Drug Device Combination Products and Expanding Biologics Market
5.2.4 Challenges
5.2.4.1 Heavy Financial Impact of Drug Wastage and Device Malfunction
5.2.4.2 Lack of Standardized Reimbursement Policies
5.2.4.3 Limited Training and Education for Healthcare Professionals
5.2.4.4 Lack of Medical Specialists and Surgeons
5.3 Industry Trends
5.3.1 Rising Popularity of Self-Administered Medicines and Home Care Settings
5.3.2 Integration of Drug Device Combination Products with Smart Connected Devices
5.4 Technology Analysis
5.4.1 Key Technologies
5.4.1.1 Wearable Technologies
5.4.1.2 Drug-Eluting Technologies
5.4.2 Complementary Technologies
5.4.2.1 Connected Health and Digital Technologies
5.4.3 Adjacent Technologies
5.4.3.1 Advanced Materials and Biopolymers
5.5 Porter's Five Forces Analysis
5.5.1 Threat of New Entrants
5.5.2 Threat of Substitutes
5.5.3 Bargaining Power of Suppliers
5.5.4 Bargaining Power of Buyers
5.5.5 Intensity of Competitive Rivalry
5.6 Key Stakeholders & Buying Criteria
5.6.1 Key Stakeholders in Buying Process
5.6.2 Key Buying Criteria
5.7 Regulatory Analysis
5.7.1 Regulatory Bodies, Government Agencies, and Other Organizations
5.7.2 Regulatory Framework
5.7.2.1 North America
5.7.2.1.1 US
5.7.2.1.2 Canada
5.7.2.2 Europe
5.7.2.3 Asia-Pacific
5.7.2.3.1 India
5.7.2.3.2 China
5.7.2.3.3 Japan
5.7.2.4 Latin America
5.7.2.5 Middle East & Africa
5.8 Patent Analysis
5.8.1 Key Patents Granted
5.9 Trade Analysis
5.9.1 Trade Analysis for Prefilled Syringes (HS Code 300431), 2019-2023
5.9.1.1 Import Data for HS Code 300431
5.9.1.2 Export Data for HS Code 300431
5.9.2 Trade Data for Transdermal Patches (HS Code 300431), 2019-2023
5.9.2.1 Import Data for HS Code 300431
5.9.2.2 Export Data for HS Code 300431
5.10 Pricing Analysis
5.10.1 Indicative Pricing of Drug Device Combination Products, by Key Player, 2024
5.10.2 Average Selling Price Trend of Injectable Drug Delivery Devices, by Key Player, 2022-2024
5.10.3 Average Selling Price Trend of Drug Delivery Combination Products, by Region, 2022-2024
5.10.3.1 Average Selling Price Trend for Pen Injectors, 2022-2024
5.10.3.2 Average Selling Price Trend for Inhalers, 2022-2024
5.10.3.3 Average Selling Price Trend for Drug-Eluting Stents, 2022-2024
5.11 Value Chain Analysis
5.12 Key Conferences & Events, 2025-2026
5.13 Unmet Needs/End-user Expectations
5.14 Adjacent Market Analysis
5.15 Ecosystem Analysis
5.15.1 Role in Ecosystem
5.16 Case Study Analysis
5.16.1 Minimed 780G Diabetes Management System to Combine Continuous Glucose Monitoring with Automated Insulin Delivery
5.16.2 Digiinhaler-Smart Inhaler for Asthma/Copd to Track Lung Function
5.16.3 Adoption of Pen Injectors by Nemera France to Improve Therapeutic Outcomes
5.17 Supply Chain Analysis
5.18 Trends/Disruptions Impacting Customers’ Businesses
5.19 Investment & Funding Scenario
5.20 Reimbursement Scenario Analysis
5.21 Clinical Pipeline Analysis
5.22 Impact of AI/Gen AI on Drug Device Combination Products Market
5.23 Impact of 2025 US Tariff on Drug Device Combination Products Market
5.23.1 Key Tariff Rates
5.23.2 Price Impact Analysis
5.23.3 Impact on Country/Region
5.23.3.1 North America
5.23.3.1.1 US
5.23.3.2 Europe
5.23.3.3 Asia-Pacific
5.23.4 Impact on End-use Industries
5.23.4.1 Hospitals & Clinics
5.23.4.2 Ambulatory Surgery Centers
5.23.4.3 Long-Term Care Facilities
5.23.4.4 Home Care Settings

6.1 Introduction
6.2 Injectable Drug Delivery Devices
6.2.1 Prefilled Syringes
6.2.1.1 Need to Eliminate Dosing Mistakes and Improve Patient Compliance to Drive Segment
6.2.2 Pen Injectors
6.2.2.1 Ease of Self-Administration and Improved Dosage Accuracy to Fuel Adoption
6.2.3 Autoinjectors
6.2.3.1 Ease of Use and Better Patient Experience to Aid Adoption in Emergency Medical Conditions
6.2.4 Wearable Injectors
6.2.4.1 Rising Popularity of Embedded Wireless Devices to Propel Market Growth
6.2.5 Needle-Free Injectors
6.2.5.1 Reduced Risk of Needlestick Injury to Fuel Market Adoption
6.3 Drug-Eluting Stents
6.3.1 Low Rate of Restenosis to Propel Market Growth
6.4 Inhalers
6.4.1 Increasing Prevalence of Respiratory Diseases to Fuel Uptake
6.5 Infusion Pumps
6.5.1 Rising Number of Surgical Procedures to Fuel Demand for Ambulatory Infusion Pumps
6.6 Transdermal Patches
6.6.1 Rising Incidence of Chronic Diseases Requiring Long-Term Medication to Aid Market Growth
6.7 Drug-Coated Balloons
6.7.1 Ability to Deliver Localized Drug Therapy with Minimal Systemic Exposure to Drive Market
6.8 Other Product Types

7.1 Introduction
7.2 Diabetes Management
7.2.1 High Geriatric Population and Increased Sedentary Lifestyle to Propel Market Growth
7.3 Respiratory Diseases
7.3.1 Rise in Urbanization, Air Pollution, and Smoking to Fuel Respiratory Ailments
7.4 Opthalmology
7.4.1 Rise of Diabetic Eye Diseases and Favorable Regulatory Scenario to Augment Market Growth
7.5 Autoimmune Diseases
7.5.1 Need for Prolonged Treatment in Chronic Patients to Spur Market Growth
7.6 Oncology
7.6.1 Drug Device Combination Products to Aid Therapeutic Precision and Optimize Patient Outcomes During Cancer Treatment
7.7 Infectious Diseases
7.7.1 Irregularized Urbanization and Poor Sanitation in Emerging Economies to Propel Market Growth
7.8 Cardiovascular Diseases
7.8.1 Increase in Sedentary Lifestyle and Changes in Eating Habits to Fuel Market Growth
7.9 Obesity Management
7.9.1 Increasing Prevalence of Obesity to Support Market Growth
7.10 Pain Management
7.10.1 Better Patient Adherence and Minimal Side Effects to Drive Adoption of Transdermal Patches
7.11 Other Applications

8.1 Introduction
8.2 Hospitals & Clinics
8.2.1 Access to Multi-Disciplinary Expertise and Procedure-based Care to Aid Market Growth
8.3 Ambulatory Surgery Centers
8.3.1 Need for Cost-Effective and High-Quality Minimally Invasive Treatment to Support Market Growth
8.4 Long-Term Care Facilities
8.4.1 Increasing Incidence of Chronic Diseases Among Elderly and Disabled Population to Drive Market
8.5 Home Care Settings
8.5.1 Increasing Demand for Patient-Centric and Cost-Effective Healthcare to Propel Market Growth
8.6 Other End-users

9.1 Introduction
9.2 North America
9.2.1 Macroeconomic Outlook for North America
9.2.2 US
9.2.2.1 US to Dominate North American Drug Device Combination Products Market During Forecast Period
9.2.3 Canada
9.2.3.1 Regulatory Modernization and Strategic Government Investments to Augment Market Growth
9.3 Europe
9.3.1 Macroeconomic Outlook for Europe
9.3.2 Germany
9.3.2.1 Technological Advancements and Strong R&D Infrastructure to Propel Market Growth
9.3.3 UK
9.3.3.1 Strong Emphasis on Personalized and Value-based Healthcare to Aid Market Growth
9.3.4 France
9.3.4.1 Strong Healthcare Infrastructure and High Investments in Biopharmaceutical Innovation to Boost Market Growth
9.3.5 Italy
9.3.5.1 Focus on Pharmaceutical-Meditech Convergence and Healthcare Modernization to Drive Market
9.3.6 Spain
9.3.6.1 Increasing Geriatric Population and Growing Focus on Home-based Treatment to Propel Market Growth
9.3.7 Rest of Europe
9.4 Asia-Pacific
9.4.1 Macroeconomic Outlook for Asia-Pacific
9.4.2 China
9.4.2.1 Favorable Government Policies and Increased Healthcare Spending to Support Market Growth
9.4.3 Japan
9.4.3.1 Advanced Healthcare Systems and Universal Reimbursement Policies to Spur Market Growth
9.4.4 India
9.4.4.1 Growing Focus on Digital Health Integration and Booming Biosimilars Sector to Drive Market
9.4.5 South Korea
9.4.5.1 Robust R&D Infrastructure and Enhanced Focus on Government-Industry Collaborations to Aid Market Growth
9.4.6 Australia
9.4.6.1 Rising Healthcare Investments by Government and Private Organizations to Boost Market Growth
9.4.7 Rest of Asia-Pacific
9.5 Latin America
9.5.1 Macroeconomic Outlook for Latin America
9.5.2 Brazil
9.5.2.1 Presence of Universal Healthcare System and High Geriatric Population to Drive Market
9.5.3 Mexico
9.5.3.1 Focus on Nearshoring and Improvement in Healthcare Sector to Drive Market
9.5.4 Rest of Latin America
9.6 Middle East & Africa
9.6.1 Macroeconomic Outlook for Middle East & Africa
9.6.2 GCC Countries
9.6.2.1 Kingdom of Saudi Arabia
9.6.2.1.1 Developed Medical Tourism and Favorable Government Initiatives to Support Market Growth
9.6.2.2 UAE
9.6.2.2.1 Increased Prevalence of Diabetes and Focus on Innovative Patient-Centric Care to Drive Market
9.6.2.3 Rest of GCC Countries
9.6.3 Rest of Middle East & Africa

10.1 Introduction
10.2 Key Player Strategies/Right to Win
10.2.1 Overview of Strategies Adopted by Key Players in Drug Device Combination Products Market
10.3 Revenue Analysis, 2020-2024
10.4 Market Share Analysis, 2024
10.4.1 Ranking of Key Market Players
10.5 Company Evaluation Matrix: Key Players, 2024
10.5.1 Stars
10.5.2 Emerging Leaders
10.5.3 Pervasive Players
10.5.4 Participants
10.5.5 Company Footprint: Key Players, 2024
10.5.5.1 Company Footprint
10.5.5.2 Region Footprint
10.5.5.3 Product Type Footprint
10.5.5.4 Application Footprint
10.6 Company Evaluation Matrix: Startups/SMEs, 2024
10.6.1 Progressive Companies
10.6.2 Responsive Companies
10.6.3 Dynamic Companies
10.6.4 Starting Blocks
10.6.5 Competitive Benchmarking: Startups/SMEs, 2024
10.6.5.1 Detailed List of Key Startups/SME Players
10.6.5.2 Competitive Benchmarking of Key Startups/SME Players
10.7 Company Valuation & Financial Metrics
10.7.1 Financial Metrics
10.7.2 Company Valuation
10.8 Brand/Product Comparison
10.9 Competitive Scenario
10.9.1 Product Launches and Approvals
10.9.2 Deals
10.9.3 Expansions
10.9.4 Other Developments

11.1 Key Players
11.1.1 Abbott
11.1.1.1 Business Overview
11.1.1.2 Products Offered
11.1.1.3 Recent Developments
11.1.1.3.1 Product Launches and Approvals
11.1.1.3.2 Deals
11.1.1.4 Analyst's View
11.1.1.4.1 Right to Win
11.1.1.4.2 Strategic Choices
11.1.1.4.3 Weaknesses & Competitive Threats
11.1.2 Eli Lilly and Company
11.1.2.1 Business Overview
11.1.2.2 Products Offered
11.1.2.3 Recent Developments
11.1.2.3.1 Product Approvals
11.1.2.3.2 Deals
11.1.2.3.3 Expansions
11.1.2.3.4 Other Developments
11.1.2.4 Analyst's View
11.1.2.4.1 Right to Win
11.1.2.4.2 Strategic Choices
11.1.2.4.3 Weaknesses & Competitive Threats
11.1.3 Medtronic
11.1.3.1 Business Overview
11.1.3.2 Products Offered
11.1.3.3 Recent Developments
11.1.3.3.1 Product Launches and Approvals
11.1.3.3.2 Deals
11.1.3.4 Analyst's View
11.1.3.4.1 Right to Win
11.1.3.4.2 Strategic Choices
11.1.3.4.3 Weaknesses & Competitive Threats
11.1.4 Novo Nordisk A/S
11.1.4.1 Business Overview
11.1.4.2 Products Offered
11.1.4.3 Recent Developments
11.1.4.3.1 Product Launches and Approvals
11.1.4.3.2 Deals
11.1.4.3.3 Expansions
11.1.4.4 Analyst's View
11.1.4.4.1 Right to Win
11.1.4.4.2 Strategic Choices
11.1.4.4.3 Weaknesses & Competitive Threats
11.1.5 Novartis AG
11.1.5.1 Business Overview
11.1.5.2 Products Offered
11.1.5.3 Recent Developments
11.1.5.3.1 Product Approvals
11.1.5.3.2 Deals
11.1.5.3.3 Expansions
11.1.5.4 Analyst's View
11.1.5.4.1 Right to Win
11.1.5.4.2 Strategic Choices
11.1.5.4.3 Weaknesses & Competitive Threats
11.1.6 Sanofi
11.1.6.1 Business Overview
11.1.6.2 Products Offered
11.1.6.3 Recent Developments
11.1.6.3.1 Product Approvals
11.1.6.3.2 Deals
11.1.6.3.3 Other Developments
11.1.7 Boston Scientific Corporation
11.1.7.1 Business Overview
11.1.7.2 Products Offered
11.1.7.3 Recent Developments
11.1.7.3.1 Product Approvals
11.1.7.3.2 Deals
11.1.8 Becton, Dickinson and Company
11.1.8.1 Business Overview
11.1.8.2 Products Offered
11.1.8.3 Recent Developments
11.1.8.3.1 Deals
11.1.8.3.2 Other Developments
11.1.9 Merck KGaA
11.1.9.1 Business Overview
11.1.9.2 Products Offered
11.1.9.3 Recent Developments
11.1.9.3.1 Deals
11.1.10 Abbvie Inc.
11.1.10.1 Business Overview
11.1.10.2 Products Offered
11.1.10.3 Recent Developments
11.1.10.3.1 Product Approvals
11.1.10.3.2 Deals
11.1.10.3.3 Expansions
11.1.11 Teva Pharmaceutical Industries Ltd.
11.1.11.1 Business Overview
11.1.11.2 Products Offered
11.1.11.3 Recent Developments
11.1.11.3.1 Product Approvals
11.1.11.3.2 Other Developments
11.1.12 Stryker
11.1.12.1 Business Overview
11.1.12.2 Products Offered
11.1.13 B. Braun SE
11.1.13.1 Business Overview
11.1.13.2 Products Offered
11.1.14 Terumo Corporation
11.1.14.1 Business Overview
11.1.14.2 Products Offered
11.1.14.3 Recent Developments
11.1.14.3.1 Product Launches and Approvals
11.2 Other Players
11.2.1 Tandem Diabetes Care, Inc.
11.2.2 Cequr Simplicity
11.2.3 Intarcia Therapeutics, Inc.
11.2.4 Halozyme, Inc.
11.2.5 Kaleo, Inc.
11.2.6 Lead Chemical Co. Ltd.
11.2.7 Purdue Pharma L.P.
11.2.8 Alvogen
11.2.9 Evolutis
11.2.10 Mundipharma International Limited
11.2.11 Sparsha Pharma International Pvt. Ltd.
11.2.12 Supernus Pharmaceuticals, Inc.
11.2.13 Alcon Inc.

12.1 Discussion Guide
12.2 Knowledgestore: The Subscription Portal
12.3 Customization Options

Table 1 Drug Device Combination Products Market: Inclusions & Exclusions
Table 2 Exchange Rates Utilized for Conversion to USD
Table 3 Drug Device Combination Products Market: Study Assumptions
Table 4 Drug Device Combination Products Market: Risk Analysis
Table 5 Diabetes Population Worldwide, 2024 vs. 2050 (Million)
Table 6 Drug Device Combination Products Market: Porter's Five Forces
Table 7 Influence of Key Stakeholders on Buying Process of Drug Device Combination Products
Table 8 Key Buying Criteria for Drug Device Combination Products
Table 9 North America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 10 Europe: Regulatory Bodies, Government Agencies, and Other Organizations
Table 11 Asia-Pacific: Regulatory Bodies, Government Agencies, and Other Organizations
Table 12 Latin America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 13 Middle East & Africa: Regulatory Bodies, Government Agencies, and Other Organizations
Table 14 US: Classification and Approval Pathways
Table 15 US: Classification of Medical Equipment
Table 16 US: Time, Cost, and Complexity of Registration Process
Table 17 Canada: Classification of Drug Device Combination Products
Table 18 Canada: Risk, Time, Cost, and Complexity of Registration Process
Table 19 Europe: European Regulatory Framework for Drug Device Combination Products
Table 20 Europe: Risk, Time, Cost, and Complexity of Registration Process
Table 21 China: Risk, Time, Cost, and Complexity of Registration Process
Table 22 Japan: Risk, Time, Cost, and Complexity of Registration Process
Table 23 Drug Device Combination Products Market: Key Patents Granted, January 2022-April 2025
Table 24 Import Data for Prefilled Syringes (HS Code 300431), by Country, 2019-2023 (USD Thousand)
Table 25 Export Data for Prefilled Syringes (HS Code 300431), by Country, 2019-2023 (USD Thousand)
Table 26 Imports Data for Transdermal Patches (HS Code 300431), by Country, 2019-2023 (USD Thousand)
Table 27 Export Data for Transdermal Patches (HS Code 300431), by Country, 2019-2023 (USD Thousand)
Table 28 Indicative Pricing of Drug Device Combination Products, by Key Player, 2024
Table 29 Average Selling Price Trend of Injectable Drug Device Delivery Devices, by Key Player, 2022-2024
Table 30 Average Selling Price Trend for Pen Injectors, by Region, 2022-2024
Table 31 Average Selling Price Trend for Inhalers, by Region, 2022-2024
Table 32 Average Selling Price Trend for Drug-Eluting Stents, by Region, 2022-2024
Table 33 Drug Device Combination Products Market: List of Key Conferences & Events, January 2025-December 2026
Table 34 Drug Device Combination Products Market: Role in Ecosystem
Table 35 Case Study 1: Minimed 780G Diabetes Management System to Combine Continuous Glucose Monitoring with Automated Insulin Delivery
Table 36 Case Study 2: Digiinhaler-Smart Inhaler for Asthma/Copd to Track Lung Function
Table 37 Case Study 3: Adoption of Pen Injectors by Nemera France to Improve Therapeutic Outcomes
Table 38 Drug Device Combination Products Market: Reimbursement Scenario Analysis
Table 39 Drug Device Combination Products Market: Clinical Pipeline Analysis (As of March 2025)
Table 40 US-Adjusted Reciprocal Tariff Rates
Table 41 Key Product-Related Tariff for Drug Device Products
Table 42 Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 43 Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 44 Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Country, 2023-2030 (USD Billion)
Table 45 List of Key Prefilled Syringes Available in Market
Table 46 Prefilled Syringes Market, by Country, 2023-2030 (USD Billion)
Table 47 Launch of Key Glp-1-Related Injectables by Major Pharmaceutical Companies, 2010-2024
Table 48 List of Key Pen Injectors Available in Market
Table 49 Pen Injectors Market, by Country, 2023-2030 (USD Billion)
Table 50 List of Key Autoinjectors Available in Market
Table 51 Autoinjectors Market, by Country 2023-2030 (USD Billion)
Table 52 Top Five Countries with Highest Number of Diabetes Patients (20-79 Years), 2021 vs. 2045 (Million)
Table 53 List of Key Wereable Injectors Available in Market
Table 54 Wearable Injectors Market, by Country, 2023-2030 (USD Billion)
Table 55 List of Key Needle-Free Injectors Available in Market
Table 56 Needle-Free Injectors Market, by Country 2023-2030 (USD Billion)
Table 57 Drug Device Combination Products Market for Drug-Eluting Stents, by Country, 2023-2030 (USD Billion)
Table 58 List of Key Inhalers Available in Market
Table 59 Drug Device Combination Products Market for Inhalers, by Country, 2023-2030 (USD Billion)
Table 60 List of Key Infusion Pumps Available in Market
Table 61 Drug Device Combination Products Market for Infusion Pumps, by Country, 2023-2030 (USD Billion)
Table 62 List of Key Transdermal Patches Available in Market
Table 63 Drug Device Combination Products Market for Transdermal Patches, by Country, 2023-2030 (USD Billion)
Table 64 List of Key Drug-Coated Balloons Available in Market
Table 65 Drug Device Combination Products Market for Drug-Coated Balloons, by Country, 2023-2030 (USD Billion)
Table 66 Drug Device Combination Products Market for Other Product Types, by Country, 2023-2030 (USD Billion)
Table 67 Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 68 Drug Device Combination Products Market for Diabetes Management, by Country, 2023-2030 (USD Billion)
Table 69 Drug Device Combination Products Market for Respiratory Diseases, by Country, 2023-2030 (USD Billion)
Table 70 Drug Device Combination Products Market for Ophthalmology, by Country, 2023-2030 (USD Billion)
Table 71 Drug Device Combination Products Market for Autoimmune Diseases, by Country, 2023-2030 (USD Billion)
Table 72 Drug Device Combination Products Market for Oncology, by Country, 2023-2030 (USD Billion)
Table 73 Key Drug Device Combination Products Available for Infectious Diseases
Table 74 Drug Device Combination Products Market for Infectious Diseases, by Country, 2023-2030 (USD Billion)
Table 75 Drug Device Combination Products Market for Cardiovascular Diseases, by Country, 2023-2030 (USD Billion)
Table 76 Key Drug Device Combination Products Available for Obesity Management
Table 77 Drug Device Combination Products Market for Obesity Management, by Country, 2023-2030 (USD Billion)
Table 78 Key Transdermal Patches Available for Pain Management
Table 79 Drug Device Combination Products Market for Pain Management, by Country, 2023-2030 (USD Billion)
Table 80 Drug Device Combination Products Market for Other Applications, by Country, 2023-2030 (USD Billion)
Table 81 Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 82 Drug Device Combination Products Market for Hospitals & Clinics, by Country, 2023-2030 (USD Billion)
Table 83 Drug Device Combination Products Market for Ambulatory Surgery Centers, by Country, 2023-2030 (USD Billion)
Table 84 Drug Device Combination Products Market for Long-Term Care Facilities, by Country, 2023-2030 (USD Billion)
Table 85 Drug Device Combination Products Market for Home Care Settings, by Country, 2023-2030 (USD Billion)
Table 86 Drug Device Combination Products Market for Other End-users, by Country, 2023-2030 (USD Billion)
Table 87 Drug Device Combination Products Market, by Region, 2023-2030 (USD Billion)
Table 88 Transdermal Patches Market, by Region, 2023-2030 (Thousand Units)
Table 89 Drug-Eluting Stents Market, by Region, 2023-2030 (Thousand Units)
Table 90 North America: Drug Device Combination Products Market, by Country, 2023-2030 (USD Billion)
Table 91 North America: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 92 North America: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 93 North America: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 94 North America: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 95 US: Key Macroindicators
Table 96 US: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 97 US: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 98 US: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 99 US: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 100 Canada: Key Macroindicators
Table 101 Canada: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 102 Canada: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 103 Canada: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 104 Canada: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 105 Europe: Drug Device Combination Products Market, by Country, 2023-2030 (USD Billion)
Table 106 Europe: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 107 Europe: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 108 Europe: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 109 Europe: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 110 Germany: Key Macroindicators
Table 111 Germany: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 112 Germany: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 113 Germany: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 114 Germany: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 115 UK: Key Macroindicators
Table 116 UK: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 117 UK: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 118 UK: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 119 UK: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 120 France: Key Macroindicators
Table 121 France: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 122 France: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 123 France: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 124 France: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 125 Italy: Key Macroindicators
Table 126 Italy: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 127 Italy: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 128 Italy: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 129 Italy: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 130 Spain: Key Macroindicators
Table 131 Spain: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 132 Spain: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 133 Spain: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 134 Spain: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 135 Rest of Europe: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 136 Rest of Europe: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 137 Rest of Europe: Drug Device Combination Products Market, Application, 2023-2030 (USD Billion)
Table 138 Rest of Europe: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 139 Asia-Pacific: Drug Device Combination Products Market, by Country, 2023-2030 (USD Billion)
Table 140 Asia-Pacific: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 141 Asia-Pacific: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 142 Asia-Pacific: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 143 Asia-Pacific: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 144 China: Key Macroindicators
Table 145 China: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 146 China: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 147 China: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 148 China: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 149 Japan: Key Macroindicators
Table 150 Japan: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 151 Japan: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 152 Japan: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 153 Japan: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 154 India: Key Macroindicators
Table 155 India: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 156 India: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 157 India: Drug Device Combination Products Market, Application, 2023-2030 (USD Billion)
Table 158 India: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 159 South Korea: Key Macroindicators
Table 160 South Korea: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 161 South Korea: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 162 South Korea: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 163 South Korea: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 164 Australia: Key Macroindicators
Table 165 Australia: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 166 Australia: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 167 Australia: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 168 Australia: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 169 Rest of Asia-Pacific: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 170 Rest of Asia-Pacific: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 171 Rest of Asia-Pacific: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 172 Rest of Asia-Pacific: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 173 Latin America: Drug Device Combination Products Market, by Country, 2023-2030 (USD Billion)
Table 174 Latin America: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 175 Latin America: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 176 Latin America: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 177 Latin America: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 178 Brazil: Key Macroindicators
Table 179 Brazil: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 180 Brazil: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 181 Brazil: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 182 Brazil: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 183 Mexico: Key Macroindicators
Table 184 Mexico: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 185 Mexico: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 186 Mexico: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 187 Mexico: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 188 Rest of Latin America: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 189 Rest of Latin America: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 190 Rest of Latin America: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 191 Rest of Latin America: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 192 Middle East & Africa: Drug Device Combination Products Market, by Region, 2023-2030 (USD Billion)
Table 193 Middle East & Africa: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 194 Middle East & Africa: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 195 Middle East & Africa: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 196 Middle East & Africa: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 197 GCC Countries: Drug Device Combination Products Market, by Country, 2023-2030 (USD Billion)
Table 198 GCC Countries: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 199 GCC Countries: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 200 GCC Countries: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 201 GCC Countries: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 202 Kingdom of Saudi Arabia: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 203 Kingdom of Saudi Arabia: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 204 Kingdom of Saudi Arabia: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 205 Kingdom of Saudi Arabia: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 206 UAE: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 207 UAE: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 208 UAE: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 209 UAE: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 210 Rest of GCC Countries: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 211 Rest of GCC Countries: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 212 Rest of GCC Countries: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 213 Rest of GCC Countries: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 214 Rest of Middle East & Africa: Drug Device Combination Products Market, by Product Type, 2023-2030 (USD Billion)
Table 215 Rest of Middle East & Africa: Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2023-2030 (USD Billion)
Table 216 Rest of Middle East & Africa: Drug Device Combination Products Market, by Application, 2023-2030 (USD Billion)
Table 217 Rest of Middle East & Africa: Drug Device Combination Products Market, by End-user, 2023-2030 (USD Billion)
Table 218 Overview of Strategies Deployed by Key Players in Drug Device Combination Products Market
Table 219 Drug Device Combination Products Market for Autoinjectors: Degree of Competition
Table 220 Drug Device Combination Products Market for Pen Injectors: Degree of Competition
Table 221 Drug Device Combination Products Market for Transdermal Patches: Degree of Competition
Table 222 Drug Device Combination Products Market: Region Footprint
Table 223 Drug Device Combination Products Market: Product Type Footprint
Table 224 Drug Device Combination Products Market: Application Footprint
Table 225 Drug Device Combination Products Market: Detailed List of Key Startups/SME Players
Table 226 Drug Device Combination Products Market: Competitive Benchmarking of Key Startups/SME Players
Table 227 Drug Device Combination Products Market: Product Launches and Approvals, January 2022-March 2025
Table 228 Drug Device Combination Products Market: Deals, January 2022-March 2025
Table 229 Drug Device Combination Products Market: Expansions, January 2022-March 2025
Table 230 Drug Device Combination Products Market: Other Developments, January 2022-March 2025
Table 231 Abbott: Company Overview
Table 232 Abbott: Products Offered
Table 233 Abbott: Product Launches and Approvals, January 2022-March 2025
Table 234 Abbott: Deals, January 2022-March 2025
Table 235 Eli Lilly and Company: Company Overview
Table 236 Eli Lilly and Company: Products Offered
Table 237 Eli Lilly and Company: Product Approvals, January 2022-March 2025
Table 238 Eli Lilly and Company: Deals, January 2022-March 2025
Table 239 Eli Lilly and Company: Expansions, January 2022-March 2025
Table 240 Eli Lilly and Company: Other Developments, January 2022-March 2025
Table 241 Medtronic: Company Overview
Table 242 Medtronic: Products Offered
Table 243 Medtronic: Product Launches and Approvals, January 2022-March 2025
Table 244 Medtronic: Deals, January 2022-March 2025
Table 245 Novo Nordisk A/S: Company Overview
Table 246 Novo Nordisk A/S: Products Offered
Table 247 Novo Nordisk A/S: Product Launches and Approvals, January 2022-March 2025
Table 248 Novo Nordisk A/S: Deals, January 2022-March 2025
Table 249 Novo Nordisk A/S: Expansions, January 2022-March 2025
Table 250 Novartis AG: Company Overview
Table 251 Novartis AG: Products Offered
Table 252 Novartis AG: Product Approvals, January 2022-March 2025
Table 253 Novartis AG: Deals, January 2022-March 2025
Table 254 Novartis AG: Expansions, January 2022-March 2025
Table 255 Sanofi: Company Overview
Table 256 Sanofi: Products Offered
Table 257 Sanofi: Product Approvals, January 2022-March 2025
Table 258 Sanofi: Deals, January 2022-March 2025
Table 259 Sanofi: Other Developments, January 2022-March 2025
Table 260 Boston Scientific Corporation: Company Overview
Table 261 Boston Scientific Corporation: Products Offered
Table 262 Boston Scientific Corporation: Product Approvals, January 2022-March 2025
Table 263 Boston Scientific Corporation: Deals, January 2022-March 2025
Table 264 Becton, Dickinson and Company: Company Overview
Table 265 Becton, Dickinson and Company: Products Offered
Table 266 Becton, Dickinson and Company: Deals, January 2022-March 2025
Table 267 Becton, Dickinson and Company: Other Developments, January 2022-March 2025
Table 268 Merck KGaA: Company Overview
Table 269 Merck KGaA: Products Offered
Table 270 Merck Kgga: Deals, January 2022-March 2025
Table 271 Abbvie Inc.: Company Overview
Table 272 Abbvie Inc.: Products Offered
Table 273 Abbvie Inc.: Product Approvals, January 2022-March 2025
Table 274 Abbvie Inc.: Deals, January 2022-March 2025
Table 275 Abbvie Inc.: Expansions, January 2022-March 2025
Table 276 Teva Pharmaceutical Industries Ltd.: Company Overview
Table 277 Teva Pharmaceutical Industries Ltd.: Products Offered
Table 278 Teva Pharmaceutical Industries Ltd.: Product Approvals, January 2022-March 2025
Table 279 Teva Pharmaceutical Industries Ltd.: Other Developments, January 2022-March 2025
Table 280 Stryker: Company Overview
Table 281 Stryker: Products Offered
Table 282 B. Braun SE: Company Overview
Table 283 B. Braun SE: Products Offered
Table 284 Terumo Corporation: Company Overview
Table 285 Terumo Corporation: Products Offered
Table 286 Terumo Corporation: Product Launches and Approvals, January 2022-March 2025
Table 287 Tandem Diabetes Care, Inc.: Company Overview
Table 288 Cequr Simplicity: Company Overview
Table 289 Intarcia Therapeutics, Inc.: Company Overview
Table 290 Halozyme, Inc.: Company Overview
Table 291 Kaleo, Inc.: Company Overview
Table 292 Lead Chemical Co. Ltd.: Company Overview
Table 293 Purdue Pharma L.P.: Company Overview
Table 294 Alvogen: Company Overview
Table 295 Evolutis: Company Overview
Table 296 Mundipharma International Limited: Company Overview
Table 297 Sparsha Pharma International Pvt. Ltd.: Company Overview
Table 298 Supernus Pharmaceuticals, Inc.: Company Overview
Table 299 Alcon Inc.: Company Overview

Figure 1 Drug Device Combination Products Market: Segments Considered & Geographical Scope
Figure 2 Drug Device Combination Products Market: Years Considered
Figure 3 Drug Device Combination Products Market: Research Design
Figure 4 Drug Device Combination Products Market: Key Data from Secondary Sources
Figure 5 Drug Device Combination Products Market: Key Primary Sources
Figure 6 Drug Device Combination Products Market: Insights from Primaries
Figure 7 Drug Device Combination Products Market: Breakdown of Primaries (By Company Type, Designation, and Region)
Figure 8 Drug Device Combination Products Market: Breakdown of Primary Interviews (Supply- and Demand-Side Participants)
Figure 9 Drug Device Combination Products Market Size Estimation: Supply-Side Analysis (2024)
Figure 10 Pen Injectors Market Size Estimation: Revenue Share Analysis (Bottom-Up Approach)
Figure 11 Autoinjectors Market Size Estimation: Revenue Share Analysis (Bottom-Up Approach)
Figure 12 Drug Device Combination Products Market: Top-Down Approach
Figure 13 Drug Device Combination Products Market: CAGR Projections (Supply Side)
Figure 14 Drug Device Combination Products Market: Data Triangulation
Figure 15 Drug Device Combination Products Market, by Product Type, 2025 vs. 2030 (USD Billion)
Figure 16 Drug Device Combination Products Market for Injectable Drug Delivery Devices, by Type, 2025 vs. 2030 (USD Billion)
Figure 17 Drug Device Combination Products Market, by Application, 2025 vs. 2030 (USD Billion)
Figure 18 Drug Device Combination Products Market, by End-user, 2025 vs. 2030 (USD Billion)
Figure 19 Regional Snapshot of Drug Device Combination Products Market
Figure 20 Increasing Number of Regulatory Approvals and Rising Incidence of Chronic Diseases to Drive Market
Figure 21 China and Diabetes Management Segment Commanded Largest Market Share in 2024
Figure 22 China to Register Highest CAGR from 2025 to 2030
Figure 23 Drug Device Combination Products Market: Drivers, Restraints, Opportunities, and Challenges
Figure 24 Disability-Adjusted Life Years for Individuals with Chronic Obstructive Pulmonary Disease (Copd) in Australia, by Age (2023)
Figure 25 Share of Global Geriatric Population (Above 60 Years), by Region, 2010 vs. 2015 vs. 2030 (Projected)
Figure 26 Drug Device Combination Products Market: Porter's Five Forces Analysis
Figure 27 Influence of Key Stakeholders on Buying Process of Drug Device Combination Products
Figure 28 Key Buying Criteria for Drug Device Combination Products
Figure 29 Drug Device Combination Products Market: Patent Publication Trends and Top Applicant Analysis (January 2014-April 2025)
Figure 30 Top Patent Applicants for Drug Device Combination Products, by Jurisdiction (January 2014-April 2025)
Figure 31 Drug Device Combination Products Market: Value Chain Analysis
Figure 32 Drug Device Combination Products Market: Adjacent Markets
Figure 33 Drug Device Combination Products Market: Ecosystem Analysis
Figure 34 Drug Device Combination Products Market: Supply Chain Analysis
Figure 35 Drug Device Combination Products Market: Trends/Disruptions Impacting Customers’ Businesses
Figure 36 Drug Device Combination Products Market: Funding and Number of Deals, 2019-2023
Figure 37 Drug Device Combination Products Market: Impact of AI/Gen AI
Figure 38 North America: Drug Device Combination Products Market Snapshot
Figure 39 Asia-Pacific: Drug Device Combination Products Market Snapshot
Figure 40 Revenue Analysis of Key Players in Drug Device Combination Products Market (2020-2024)
Figure 41 Market Share Analysis of Key Players in Autoinjectors Market (2024)
Figure 42 Market Share Analysis of Key Players in Pen Injectors Market (2024)
Figure 43 Market Share Analysis of Key Players in Transdermal Patches Market (2024)
Figure 44 Ranking of Key Players in Drug Device Combination Products Market (2024)
Figure 45 Drug Device Combination Products Market: Company Evaluation Matrix (Key Players), 2024
Figure 46 Drug Device Combination Products Market: Company Footprint
Figure 47 Drug Device Combination Products Market: Company Evaluation Matrix (Startups/SMEs), 2024
Figure 48 EV/EBITDA of Key Vendors
Figure 49 Year-To-Date (YTD) Price Total Return and 5-Year Stock Beta of Key Vendors
Figure 50 Drug Device Combination Products Market: Brand/Product Comparative Analysis
Figure 51 Abbott: Company Snapshot
Figure 52 Eli Lilly and Company: Company Snapshot
Figure 53 Medtronic: Company Snapshot
Figure 54 Novo Nordisk A/S: Company Snapshot
Figure 55 Novartis AG: Company Snapshot
Figure 56 Sanofi: Company Snapshot
Figure 57 Boston Scientific Corporation: Company Snapshot
Figure 58 Becton, Dickinson and Company: Company Snapshot
Figure 59 Merck KGaA: Company Snapshot
Figure 60 Abbvie Inc.: Company Snapshot
Figure 61 Teva Pharmaceutical Industries Ltd.: Company Snapshot
Figure 62 Stryker: Company Snapshot
Figure 63 B. Braun SE: Company Snapshot
Figure 64 Terumo Corporation: Company Snapshot